[1]
Babon, J.J.; Lucet, I.S.; Murphy, J.M.; Nicola, N.A.; Varghese, L.N. The molecular regulation of Janus kinase (JAK) activation. Biochem. J., 2014, 462, 1-13.
[2]
Menet, C.J.; Mammoliti, O.; López-Ramos, M. Progress toward JAK1-selective inhibitors. Future Med. Chem., 2015, 7, 203-235.
[3]
Roskoski, R., Jr Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol. Res., 2016, 111, 784-803.
[4]
Yamaoka, K.; Saharinen, P.; Pesu, M.; Holt, V.E., III; Silvennoinen, O.; O’Shea, J.J. The Janus kinases (Jaks). Genome Biol., 2004, 5, 253.
[5]
Darnell, J.E., Jr; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994, 264, 1415-1421.
[6]
Jones, A.V.; Kreil, S.; Zoi, K.; Waghorn, K.; Curtis, C.; Zhang, L.; Score, J.; Seear, R.; Chase, A.J.; Grand, F.H.; White, H.; Zoi, C.; Loukopoulos, D.; Terpos, E.; Vervessou, E.C.; Schultheis, B.; Emig, M.; Ernst, T.; Lengfelder, E.; Hehlmann, R.; Hochhaus, A.; Oscier, D.; Silver, R.T.; Reiter, A.; Cross, N.C. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005, 106, 2162-2168.
[7]
Quintás-Cardama, A.; Verstovsek, S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res., 2013, 19, 1933-1940.
[8]
Ghoreschi, K.; Laurence, A.; O’Shea, J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol., 2009, 10, 356-360.
[9]
Ghoreschi, K.; Gadina, M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp. Dermatol., 2014, 23, 7-11.
[10]
Saeed, I.; McLornan, D.; Harrison, C.N. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Rev. Hematol., 2017, 10, 617-625.
[11]
Deisseroth, A.; Kaminskas, E.; Grillo, J.; Chen, W.; Saber, H.; Lu, H.L.; Rothmann, M.D.; Brar, S.; Wang, J.; Garnett, C.; Bullock, J.; Burke, L.B.; Rahman, A.; Sridhara, R.; Farrell, A.; Pazdur, R.U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin. Cancer Res., 2012, 18, 3212-3217.
[12]
Barosi, G.; Rosti, V.; Gale, R.P. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. OncoTargets Ther., 2015, 18, 1091-1102.
[13]
van Vollenhoven, R.F. Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy. Nat. Rev. Rheumatol., 2013, 9, 70-72.
[14]
Gonzales, A.J.; Bowman, J.W.; Fici, G.J.; Zhang, M.; Mann, D.W.; Mitton-Fry, M. Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J. Vet. Pharmacol. Ther., 2014, 37, 317-324.
[15]
Markham, A. Baricitinib: First global approval. Drugs, 2017, 77, 697-704.
[16]
Williams, N.K.; Bamert, R.S.; Patel, O.; Wang, C.; Walden, P.M.; Wilks, A.F.; Fantino, E.; Rossjohn, J.; Lucet, I.S. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol., 2009, 387, 219-232.
[17]
Musumeci, F.; Sanna, M.; Grossi, G.; Brullo, C.; Fallacara, A.L.; Schenone, S. Pyrrolo [2,3-d]pyrimidines as kinase inhibitors. Curr. Med. Chem., 2017, 24, 2059-2085.
[18]
Nerviano Medical Sciences, S.R.L. Substituted pyrroles as
kinase inhibitors and their preparation. WO 2014019908, 2014.
[19]
Nerviano Medical Sciences, S.R.L. Preparation of pyrimidinylpyrrole
derivatives for use as kinase inhibitors. WO
2012143248, 2012.
[20]
Brasca, M.G.; Nesi, M.; Avanzi, N.; Ballinari, D.; Bandiera, T.; Bertrand, J.; Bindi, S.; Canevari, G.; Carenzi, D.; Casero, D.; Ceriani, L.; Ciomei, M.; Cirla, A.; Colombo, M.; Cribioli, S.; Cristiani, C.; Della Vedova, F.; Fachin, G.; Fasolini, M.; Felder, E.R.; Galvani, A.; Isacchi, A.; Mirizzi, D.; Motto, I.; Panzeri, A.; Pesenti, E.; Vianello, P.; Gnocchi, P.; Donati, D. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors. Bioorg. Med. Chem., 2014, 22, 4998-5012.
[21]
Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole
carboxamides as Janus kinase inhibitors. WO 2013040863, 2013.
[22]
Merck Sharp & Dohme Corp. Pyrazole carboxamides as
Janus kinase inhibitors. WO 2013041042, 2013.
[23]
Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides
as Janus kinase inhibitors. WO 2013043962, 2013.
[24]
Merck Sharp & Dohme Corp. Acyclic cyanoethylpyrazoles
as Janus kinase inhibitors. WO 2013043964, 2013.
[25]
Incyte Corporation. Preparation of bipyrazole derivatives as
JAK kinase inhibitors. WO 2014186706, 2014.
[26]
Liang, X.; Huang, Y.; Zang, J.; Gao, Q.; Wang, B.; Xu, W.; Zhang, Y. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. Bioorg. Med. Chem., 2016, 24, 2660-2672.
[27]
Liang, X.; Zang, J.; Zhu, M.; Gao, Q.; Wang, B.; Xu, W.; Zhang, Y. Design, synthesis, and antitumor evaluation of 4-amino-(1H)-pyrazole derivatives as JAKs inhibitors. ACS Med. Chem. Lett., 2016, 7, 950-955.
[28]
Sang, Y-L.; Duan, Y-T.; Qiu, H-Y.; Wang, P-F.; Makawana, J.A.; Wang, Z-C.; Zhu, H-L.; He, Z-X. Design, synthesis, biological evaluation and molecular docking of novel metronidazole derivatives as selective and potent JAK3 inhibitors. RSC Advances, 2014, 4, 16694-16704.
[29]
Exelixis Inc. 4-Aryl-2-amino-pyrimidines or 4-aryl-2-
aminoalkyl-pyrimidines as JAK-2 modulators and methods
of use. WO 2007089768, 2007.
[30]
Targegen Inc. Bi-aryl meta-pyrimidine inhibitors of kinases.
WO 2007053452, 2007.
[31]
Cytopia RES Pty Ltd. Phenyl amino pyrimidine compounds
and uses thereof. WO 2008109943, 2008.
[32]
YM Biosciences Australia Pty Ltd. Preparation of phenyl
amino pyrimidine bicyclic compounds useful as protein
kinase inhibitors. WO 2014000032, 2014.
[33]
Calitor Sciences LLC, Sunshine Lake Pharma Co., Ltd.
Substituted heteroaryl compounds and methods of use. WO
2015094803, 2015.
[34]
Dana-Faber Cancer Institute, Inc. Janus kinase inhibitors
and uses thereof. WO 2015164614, 2015.
[35]
Joshi, M.; Rizvi, S.M.; Belani, C.P. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag. Res., 2015, 7, 75-82.
[36]
de Claro, R.A.; McGinn, K.M.; Verdun, N.; Lee, S.L.; Chiu, H.J.; Saber, H.; Brower, M.E.; Chang, C.J.; Pfuma, E.; Habtemariam, B.; Bullock, J.; Wang, Y.; Nie, L.; Chen, X.H.; Lu, D.R.; Al-Hakim, A.; Kane, R.C.; Kaminskas, E.; Justice, R.; Farrell, A.T.; Pazdur, R. FDA approval: Ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin. Cancer Res., 2015, 21, 3586-3590.
[37]
Tan, L.; Akahane, K.; McNally, R.; Reyskens, K.M.; Ficarro, S.B.; Liu, S.; Herter-Sprie, G.S.; Koyama, S.; Pattison, M.J.; Labella, K.; Johannessen, L.; Akbay, E.A.; Wong, K.K.; Frank, D.A.; Marto, J.A.; Look, T.A.; Arthur, J.S.; Eck, M.J.; Gray, N.S. Development of selective covalent Janus kinase 3 inhibitors. J. Med. Chem., 2015, 58, 6589-6606.
[38]
Almirall, S.A. Pyrazolopyrimidin-2-yl derivatives as JAK
inhibitors. WO 2015086693, 2015.
[39]
Almirall, S.A. Imidazolopyrimidin-2-yl derivatives as JAK
inhibitors. WO 2015091531, 2015.
[40]
Almirall, S.A. Preparation of 2-(pyrazolopyridin-3-yl)
pyrimidine derivatives as JAK inhibitors. WO 2016198663, 2016.
[41]
Portola Pharmaceuticals, Inc. Pyridazine compounds as
JAK inhibitors. WO 2015123453, 2015.
[42]
Vertex Pharmaceuticals Inc. Azaindoles useful as inhibitors
of Janus kinases. WO 2007084557, 2007.
[43]
Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors.
WO 2007077949, 2007.
[44]
Farmer, L.J.; Ledeboer, M.W.; Hoock, T.; Arnost, M.J.; Bethiel, R.S.; Bennani, Y.L.; Black, J.J.; Brummel, C.L.; Chakilam, A.; Dorsch, W.A.; Fan, B.; Cochran, J.E.; Halas, S.; Harrington, E.M.; Hogan, J.K.; Howe, D.; Huang, H.; Jacobs, D.H.; Laitinen, L.M.; Liao, S.; Mahajan, S.; Marone, V.; Martinez-Botella, G.; McCarthy, P.; Messersmith, D.; Namchuk, M.; Oh, L.; Penney, M.S.; Pierce, A.C.; Raybuck, S.A.; Rugg, A.; Salituro, F.G.; Saxena, K.; Shannon, D.; Shlyakter, D.; Swenson, L.; Tian, S.K.; Town, C.; Wang, J.; Wang, T.; Wannamaker, M.W.; Winquist, R.J.; Zuccola, H.J. Discovery of VX-509 (Decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases. J. Med. Chem., 2015, 58, 7195-7216.
[45]
Iwata, S.; Tanaka, Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol., 2016, 12, 1047-1057.
[46]
Merck Sharp & Dohme Corp. Azaindoles as Janus kinase
inhibitors. WO 2013052355, 2013.
[47]
Nakajima, Y.; Inoue, T.; Nakai, K.; Mukoyoshi, K.; Hamaguchi, H.; Hatanaka, K.; Sasaki, H.; Tanaka, A.; Takahashi, F.; Kunikawa, S.; Usuda, H.; Moritomo, A.; Higashi, Y.; Inami, M.; Shirakami, S. Synthesis and evaluation of novel 1H-pyrrolo [2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. Bioorg. Med. Chem., 2015, 23, 4871-4883.
[48]
Astellas Pharma Inc. Condensed pyridine compounds.
WO 2008084861, 2008.
[49]
Novartis Tiergesundheit AG. Preparation of heterocyclylsubstituted
aminosulfonylmethyl cyclohexanes as Janus
kinase inhibitors. WO 2015144773, 2015.
[50]
Incyte Corporation. Preparation of piperidin-4-yl azetidine
derivatives as JAK1 inhibitors. WO 2011112662, 2011.
[52]
Bissonnette, R.; Luchi, M.; Fidelus-Gort, R.; Jackson, S.; Zhang, H.; Flores, R.; Newton, R.; Scherle, P.; Yeleswaram, S.; Chen, X.; Menter, A. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral Janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J. Dermatolog. Treat., 2016, 27, 332-338.
[53]
Mascarenhas, J.O.; Talpaz, M.; Gupta, V.; Foltz, L.M.; Savona, M.R.; Paquette, R.; Turner, A.R.; Coughlin, P.; Winton, E.; Burn, T.C.; O’Neill, P.; Clark, J.; Hunter, D.; Assad, A.; Hoffman, R.; Verstovsek, S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica, 2017, 102, 327-335.
[54]
Incyte Corporation. Cyclohexyl azetidine derivatives as
JAK inhibitors. WO 2013026025, 2013.
[55]
Incyte Corporation. Piperidinylcylobutyl substituted pyrrolopyridine
and pyrrolopyrimidine derivatives as JAK inhibitors.
WO 2013173720, 2013.
[56]
Merck Sharp & Dohme Corp. Preparation of pyrrolopyrimidines
as Janus kinase inhibitors. WO
2013085802, 2013.
[57]
Elwood, F.; Witter, D.J.; Piesvaux, J.; Kraybill, B.; Bays, N.; Alpert, C.; Goldenblatt, P.; Qu, Y.; Ivanovska, I.; Lee, H.H.; Chiu, C.S.; Tang, H.; Scott, M.E.; Deshmukh, S.V.; Zielstorff, M.; Byford, A.; Chakravarthy, K.; Dorosh, L.; Rivkin, A.; Klappenbach, J.; Pan, B.S.; Kariv, I.; Dinsmore, C.; Slipetz, D.; Dandliker, P.J. Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor. J. Pharmacol. Exp. Ther., 2017, 361, 229-244.
[58]
Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivative as inhibitors
of Janus-related kinases (JAK) and their preparation. WO
2014128591, 2014.
[59]
Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b] pyrazinyl
and pyrrolo[2,3-d]pyridinyl acrylamides as JAK inhibitor
and their preparation. WO 2015083028, 2015.
[60]
Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b] pyrazinyl,
pyrrolo[2,3-b]pyridinyl acrylamides and epoxides
thereof. WO 2016178110, 2016.
[61]
Thorarensen, A.; Dowty, M.E.; Banker, M.E.; Juba, B.; Jussif, J.; Lin, T.; Vincent, F.; Czerwinski, R.M.; Casimiro-Garcia, A.; Unwalla, R.; Trujillo, J.I.; Liang, S.; Balbo, P.; Che, Y.; Gilbert, A.M.; Brown, M.F.; Hayward, M.; Montgomery, J.; Leung, L.; Yang, X.; Soucy, S.; Hegen, M.; Coe, J.; Langille, J.; Vajdos, F.; Chrencik, J.; Telliez, J.B. Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo [2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans. J. Med. Chem., 2017, 60, 1971-1993.
[62]
Telliez, J.B.; Dowty, M.E.; Wang, L.; Jussif, J.; Lin, T.; Li, L.; Moy, E.; Balbo, P.; Li, W.; Zhao, Y.; Crouse, K.; Dickinson, C.; Symanowicz, P.; Hegen, M.; Banker, M.E.; Vincent, F.; Unwalla, R.; Liang, S.; Gilbert, A.M.; Brown, M.F.; Hayward, M.; Montgomery, J.; Yang, X.; Bauman, J.; Trujillo, J.I.; Casimiro-Garcia, A.; Vajdos, F.F.; Leung, L.; Geoghegan, K.F.; Quazi, A.; Xuan, D.; Jones, L.; Hett, E.; Wright, K.; Clark, J.D.; Thorarensen, A. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem. Biol., 2016, 11, 3442-3451.
[64]
Wang, T.; Liu, X.; Hao, M.; Qiao, J.; Ju, C.; Xue, L.; Zhang, C. Design, synthesis and evaluation of pyrrolo [2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors. Bioorg. Med. Chem. Lett., 2016, 26, 2936-2941.
[65]
Lee, S.M.; Yoon, K.B.; Lee, H.J.; Kim, J.; Chung, Y.K.; Cho, W.J.; Mukai, C.; Choi, S.; Kang, K.W.; Han, S.Y.; Ko, H.; Kim, Y.C. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3. Bioorg. Med. Chem., 2016, 24, 5036-5046.
[66]
Soth, M.; Hermann, J.C.; Yee, C.; Alam, M.; Barnett, J.W.; Berry, P.; Browner, M.F.; Frank, K.; Frauchiger, S.; Harris, S.; He, Y.; Hekmat-Nejad, M.; Hendricks, T.; Henningsen, R.; Hilgenkamp, R.; Ho, H.; Hoffman, A.; Hsu, P.Y.; Hu, D.Q.; Itano, A.; Jaime-Figueroa, S.; Jahangir, A.; Jin, S.; Kuglstatter, A.; Kutach, A.K.; Liao, C.; Lynch, S.; Menke, J.; Niu, L.; Patel, V.; Railkar, A.; Roy, D.; Shao, A.; Shaw, D.; Steiner, S.; Sun, Y.; Tan, S.L.; Wang, S.; Vu, M.D. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models. J. Med. Chem., 2013, 56, 345-356.
[67]
Jaime-Figueroa, S.; De Vicente, J.; Hermann, J.; Jahangir, A.; Jin, S.; Kuglstatter, A.; Lynch, S.M.; Menke, J.; Niu, L.; Patel, V.; Shao, A.; Soth, M.; Vu, M.D.; Yee, C. Discovery of a series of novel 5H-pyrrolo [2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 2522-2526.
[68]
de Vicente, J.; Lemoine, R.; Bartlett, M.; Hermann, J.C.; Hekmat-Nejad, M.; Henningsen, R.; Jin, S.; Kuglstatter, A.; Li, H.; Lovey, A.J.; Menke, J.; Niu, L.; Patel, V.; Petersen, A.; Setti, L.; Shao, A.; Tivitmahaisoon, P.; Vu, M.D.; Soth, M. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines. Bioorg. Med. Chem. Lett., 2014, 24, 4969-4975.
[69]
Duan, J.J.; Lu, Z.; Jiang, B.; Yang, B.V.; Doweyko, L.M.; Nirschl, D.S.; Haque, L.E.; Lin, S.; Brown, G.; Hynes, J., Jr; Tokarski, J.S.; Sack, J.S.; Khan, J.; Lippy, J.S.; Zhang, R.F.; Pitt, S.; Shen, G.; Pitts, W.J.; Carter, P.H.; Barrish, J.C.; Nadler, S.G.; Salter-Cid, L.M.; McKinnon, M.; Fura, A.; Schieven, G.L.; Wrobleski, S.T. Discovery of pyrrolo [1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors. Bioorg. Med. Chem. Lett., 2014, 24, 5721-5726.
[70]
Bristol-Myers Squibb Co. Pyrrolopyridazine Jak3 inhibitors
and their use for the treatment of inflammatory and autoimmune
diseases. WO 2012125886, 2012.
[71]
Pfizer Ltd. Indazoles. WO 2013014567, 2013.
[72]
Jones, P.; Storer, R.I.; Sabnis, Y.A.; Wakenhut, F.M.; Whitlock, G.A.; England, K.S.; Mukaiyama, T.; Dehnhardt, C.M.; Coe, J.W.; Kortum, S.W.; Chrencik, J.E.; Brown, D.G.; Jones, R.M.; Murphy, J.R.; Yeoh, T.; Morgan, P.; Kilty, I. Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin. J. Med. Chem., 2017, 60, 767-786.
[73]
Topivert Pharma Ltd. Preparation of 4,5,6,7-tetrahydro-1Himidazo[
4,5-c]pyridine and 1,4,5,6,7,8-hexahydro-1Himidazo[
4,5-d]diazepine derivatives as Janus kinase inhibitors.
WO 2017077283, 2017.
[74]
Topivert Pharma Ltd. Preparation of 4,5,6,7-tetrahydro-1Himidazo[
4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo
[4,5-d]azepine derivatives as Janus kinase inhibitors. WO
2017077288, 2017.
[75]
Ritzén, A.; Sørensen, M.D.; Dack, K.N.; Greve, D.R.; Jerre, A.; Carnerup, M.A.; Rytved, K.A.; Bagger-Bahnsen, J. Fragment-based discovery of 6-arylindazole JAK inhibitors. ACS Med. Chem. Lett., 2016, 7, 641-646.
[76]
Cellzome Ltd. Pyrazolo[4,3-c]pyridine derivatives as Jak
inhibitors. WO 2013017479, 2013.
[77]
Cellzome Ltd. Pyrazolo[4,3-c]pyridine derivatives as Jak
inhibitors. WO 2013017480, 2013.
[78]
Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo
pyridones as Janus kinase inhibitors. WO 2014146246, 2014.
[79]
Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo
pyridones as Janus kinase inhibitors. WO
2014146249, 2014.
[80]
Merck Sharp & Dohme Corp. N-(2-cyano heterocyclyl)
pyrazolo pyridones as Janus kinase inhibitors. WO
2014146492, 2014.
[81]
Merck Sharp & Dohme Corp. Acyclic cyanoethylpypyrazolo
pyridones as Janus kinase inhibitors. WO 2014146493, 2014.
[82]
Merck Sharp & Dohme Corp. Ethyl N-Boc piperidinyl
pyrazolo pyridones as Janus kinase inhibitors. 2016 WO
2016064935, 2016.
[83]
Merck Sharp & Dohme Corp. Ethyl N-Boc piperidinyl
pyrazolo pyridones as Janus kinase inhibitors. WO
2016061751, 2016.
[84]
Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines as
JAK inhibitors and their preparation. WO 2015173683, 2015.
[85]
Calitor Sciences LLC, Sunshine Lake Pharma Co., Ltd.
Preparation of substituted pyrazolo[1,5-a]pyrimidine-3-
carboxamide derivatives as JAK kinase inhibitors. WO
2015073267, 2015.
[86]
Celon Pharma S.A. Pyrazolo[1,5-a]pyrimidine derivatives
as kinase JAK-2 inhibitors. WO 2015118434, 2015.
[87]
F. Hoffmann-La Roche AG. 5-Chloro-2-
difluoromethoxyphenyl pyrazolopyrimidine compounds
which are JAK inhibitors. WO 2015177326, 2015.
[88]
Array Biopharma Inc. 4,6-Disubstituted-pyrazolo[1,5-
a]pyrazines as Janus kinase inhibitors and their preparation.
WO 2016090285, 2016.
[89]
Meyer, S.C.; Keller, M.D.; Chiu, S.; Koppikar, P.; Guryanova, O.A.; Rapaport, F.; Xu, K.; Manova, K.; Pankov, D.; O’Reilly, R.J.; Kleppe, M.; McKenney, A.S.; Shih, A.H.; Shank, K.; Ahn, J.; Papalexi, E.; Spitzer, B.; Socci, N.; Viale, A.; Mandon, E.; Ebel, N.; Andraos, R.; Rubert, J.; Dammassa, E.; Romanet, V.; Dölemeyer, A.; Zender, M.; Heinlein, M.; Rampal, R.; Weinberg, R.S.; Hoffman, R.; Sellers, W.R.; Hofmann, F.; Murakami, M.; Baffert, F.; Gaul, C.; Radimerski, T.; Levine, R.L. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell, 2015, 28, 15-28.
[90]
Wu, S.C.; Li, L.S.; Kopp, N.; Montero, J.; Chapuy, B.; Yoda, A.; Christie, A.L.; Liu, H.; Christodoulou, A.; van Bodegom, D.; van der Zwet, J.; Layer, J.V.; Tivey, T.; Lane, A.A.; Ryan, J.A.; Ng, S.Y.; DeAngelo, D.J.; Stone, R.M.; Steensma, D.; Wadleigh, M.; Harris, M.; Mandon, E.; Ebel, N.; Andraos, R.; Romanet, V.; Dölemeyer, A.; Sterker, D.; Zender, M.; Rodig, S.J.; Murakami, M.; Hofmann, F.; Kuo, F.; Eck, M.J.; Silverman, L.B.; Sallan, S.E.; Letai, A.; Baffert, F.; Vangrevelinghe, E.; Radimerski, T.; Gaul, C.; Weinstock, D.M. Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia. Cancer Cell, 2015, 28, 29-41.
[91]
Kim, M.K.; Shin, H.; Park, K.S.; Kim, H.; Park, J.; Kim, K.; Nam, J.; Choo, H.; Chong, Y. Benzimidazole derivatives as potent JAK1-selective inhibitors. J. Med. Chem., 2015, 58, 7596-7602.
[92]
Simov, V.; Deshmuckh, S.V.; Dinsmore, C.J.; Elwood, F.; Fernandez, R.B.; Garcia, Y.; Gibeau, C.; Gunaydin, H.; Jung, J.; Katz, J.D.; Kraybill, B.; Lapointe, B.; Patel, S.B.; Siu, T.; Su, H.; Young, J.R. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors. Bioorg. Med. Chem. Lett., 2016, 26, 1803-1808.
[93]
JN Therapeutics. Preparation of substituted imidazo[1,2-
a]pyridin-2-ylamine compounds for treating, preventing, or
ameliorating one or more symptoms of a Janus kinasemediated
disease. WO 2016119700, 2016.
[94]
Vasbinder, M.M.; Alimzhanov, M.; Augustin, M.; Bebernitz, G.; Bell, K.; Chuaqui, C.; Deegan, T.; Ferguson, A.D.; Goodwin, K.; Huszar, D.; Kawatkar, A.; Kawatkar, S.; Read, J.; Shi, J.; Steinbacher, S.; Steuber, H.; Su, Q.; Toader, D.; Wang, H.; Woessner, R.; Wu, A.; Ye, M.; Zinda, M. Identification of azabenzimidazoles as potent JAK1 selective inhibitors. Bioorg. Med. Chem. Lett., 2016, 26, 60-67.
[95]
Galapagos NV. Imidazo[4,5-c]pyridine derivatives as JAK
kinase inhibitors useful for the treatment of degenerative and inflammatory diseases and their preparation. WO
2013117645, 2013.
[96]
Galapagos NV. Preparation of N-[4-ethyl-6-[1-
(methylsulfonyl)-3-azetidinyl]-3-pyridinyl]-N,1-dimethyl-
1H-imidazo[4,5-c]pyridin-6-amine as JAK inhibitor useful
for the treatment of degenerative and inflammatory diseases.
WO 2014111380, 2014.
[97]
Galapagos NV. Imidazo[4,5-c]pyridine derivatives useful
for the treatment of degenerative and inflammatory diseases.
WO 2013117645, 2013.
[98]
Galapagos NV. Novel compound useful for the treatment of
degenerative and inflammatory diseases. WO 2013117646, 2013.
[99]
Galapagos NV. Imidazo[4,5-c]pyridine derivatives as JAK
kinase inhibitors useful for the treatment of degenerative
and inflammatory diseases and their preparation WO
2013117649, 2013.
[100]
Galapagos NV. Preparation of pyridoimidazoles and pharmaceutical
compositions thereof for the treatment of inflammatory
disorders. WO 2017012647, 2017.
[101]
Eli-Lilly & Co. Amino pyrazole compounds. WO
2010074947, 2010.
[102]
Ma, L.; Clayton, J.R.; Walgren, R.A.; Zhao, B.; Evans, R.J.; Smith, M.C.; Heinz-Taheny, K.M.; Kreklau, E.L.; Bloem, L.; Pitou, C.; Shen, W.; Strelow, J.M.; Halstead, C.; Rempala, M.E.; Parthasarathy, S.; Gillig, J.R.; Heinz, L.J.; Pei, H.; Wang, Y.; Stancato, L.F.; Dowless, M.S.; Iversen, P.W.; Burkholder, T.P. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J., 2013, 3e109
[104]
Celon Pharma S.A. Preparation of imidazo[1,2-b]pyridazin-
6-amine derivatives as JAK2 inhibitors. WO 2014020531, 2014.
[105]
Array Biopharma Inc. Preparation of imidazopyrimidine
derivatives for use as Jak kinase inhibitors. WO
2013055645, 2013.
[106]
Ligand Pharmaceuticals Inc. Janus kinase inhibitor compounds
and methods. WO 2013025628, 2013.
[107]
Galapagos NV. Novel compounds useful for the treatment
of degenerative and inflammatory diseases. WO
2010010190, 2010.
[108]
Menet, C.J.; Fletcher, S.R.; Van Lommen, G.; Geney, R.; Blanc, J.; Smits, K.; Jouannigot, N.; Deprez, P.; van der Aar, E.M.; Clement-Lacroix, P.; Lepescheux, L.; Galien, R.; Vayssiere, B.; Nelles, L.; Christophe, T.; Brys, R.; Uhring, M.; Ciesielski, F.; Van Rompaey, L. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J. Med. Chem., 2014, 57, 9323-9342.
[109]
Danese, S.; Fiorino, G.; Peyrin-Biroulet, L. Filgotinib in Crohn’s disease: JAK is back. Gastroenterology, 2017, 153, 603-605.
[110]
Taylor, P.C.; Abdul Azeez, M.; Kiriakidis, S. Filgotinib for the treatment of rheumatoid arthritis. Expert Opin. Investig. Drugs, 2017, 26, 1181-1187.
[112]
Galapagos NV. Aminotriazolopyridine for use in the treatment
of inflammation, and pharmaceutical compositions
thereof. WO 2013189771, 2013.
[113]
F. Hoffmann-La Roche AG. Preparation of triazolopyridine
compounds as Janus kinase inhibitors and methods of use
thereof. WO 2016139212, 2016.
[114]
Labadie, S.; Barrett, K.; Blair, W.S.; Chang, C.; Deshmukh, G.; Eigenbrot, C.; Gibbons, P.; Johnson, A.; Kenny, J.R.; Kohli, P.B.; Liimatta, M.; Lupardus, P.J.; Shia, S.; Steffek, M.; Ubhayakar, S.; van Abbema, A.; Zak, M. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 5923-5930.
[115]
Theravance Biopharma R&D IP, LLC. Naphthyridine compounds
as Jak kinase inhibitors. WO 2016191524 2016.
[116]
Jiangsu Simcere Pharmaceutical Co., Ltd. Pyrimidine compounds
and use thereof. WO 2014075318, 2014.
[117]
Wang, Y.; Huang, W.; Xin, M.; Chen, P.; Gui, L.; Zhao, X.; Tang, F.; Wang, J.; Liu, F. Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors. Bioorg. Med. Chem., 2017, 25, 75-83.
[118]
Gehringer, M.; Pfaffenrot, E.; Bauer, S.; Laufer, S.A. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes. ChemMedChem, 2014, 9, 277-281.
[119]
Astellas Pharma Inc. Fused pyrrolopyridine derivative. WO
2010119875, 2010.
[120]
Nakamura, K.; Inami, M.; Morio, H.; Okuma, K.; Ito, M.; Noto, T.; Shirakami, S.; Hirose, J.; Morokata, T. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. Eur. J. Pharmacol., 2017, 796, 69-75.
[121]
Bristol-Myers Squibb Co. JAK2 inhibitors and their use for
the treatment of myeloproliferative diseases and cancer.
WO 2011028864, 2011.
[122]
Wan, H.; Schroeder, G.M.; Hart, A.C.; Inghrim, J.; Grebinski, J.; Tokarski, J.S.; Lorenzi, M.V.; You, D.; Mcdevitt, T.; Penhallow, B.; Vuppugalla, R.; Zhang, Y.; Gu, X.; Iyer, R.; Lombardo, L.J.; Trainor, G.L.; Ruepp, S.; Lippy, J.; Blat, Y.; Sack, J.S.; Khan, J.A.; Stefanski, K.; Sleczka, B.; Mathur, A.; Sun, J.H.; Wong, M.K.; Wu, D.R.; Li, P.; Gupta, A.; Arunachalam, P.N.; Pragalathan, B.; Narayanan, S.; Nanjundaswamy, K.C.; Kuppusamy, P.; Purandare, A.V. Discovery of a highly selective JAK2 Inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms. ACS Med. Chem. Lett., 2015, 6, 850-855.
[123]
Mace, T.A.; Shakya, R.; Elnaggar, O.; Wilson, K.; Komar, H.M.; Yang, J.; Pitarresi, J.R.; Young, G.S.; Ostrowski, M.C.; Ludwig, T.; Bekaii-Saab, T.; Bloomston, M.; Lesinski, G.B. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget, 2015, 6, 44509-44522.
[124]
Pomicter, A.D.; Eiring, A.M.; Senina, A.V.; Zabriskie, M.S.; Marvin, J.E.; Prchal, J.T.; O’Hare, T.; Deininger, M.W. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp. Hematol., 2015, 43, 537-545.
[125]
Hart, A.C.; Schroeder, G.M.; Wan, H.; Grebinski, J.; Inghrim, J.; Kempson, J.; Guo, J.; Pitts, W.J.; Tokarski, J.S.; Sack, J.S.; Khan, J.A.; Lippy, J.; Lorenzi, M.V.; You, D.; McDevitt, T.; Vuppugalla, R.; Zhang, Y.; Lombardo, L.J.; Trainor, G.L.; Purandare, A.V. Structure-based design of selective Janus kinase 2 imidazo [4,5-d]pyrrolo [2,3-b]pyridine inhibitors. ACS Med. Chem. Lett., 2015, 6, 845-849.
[126]
Gehringer, M.; Forster, M.; Pfaffenrot, E.; Bauer, S.M.; Laufer, S.A. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres. ChemMedChem, 2014, 9, 2516-2527.
[127]
F. Hoffmann-La Roche AG. Fused tricyclic compounds for
use as inhibitors of Janus kinases and their preparation. WO
2013007765, 2013.
[128]
Goedken, E.R.; Argiriadi, M.A.; Banach, D.L.; Fiamengo, B.A.; Foley, S.E.; Frank, K.E.; George, J.S.; Harris, C.M.; Hobson, A.D.; Ihle, D.C.; Marcotte, D.; Merta, P.J.; Michalak, M.E.; Murdock, S.E.; Tomlinson, M.J.; Voss, J.W. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. J. Biol. Chem., 2015, 290, 4573-4589.
[129]
Yamagishi, H.; Shirakami, S.; Nakajima, Y.; Tanaka, A.; Takahashi, F.; Hamaguchi, H.; Hatanaka, K.; Moritomo, A.; Inami, M.; Higashi, Y.; Inoue, T. Discovery of 3,6-dihydroimidazo [4,5-d]pyrrolo [2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors. Bioorg. Med. Chem., 2015, 23, 4846-4859.
[130]
Forster, M.; Chaikuad, A.; Bauer, S.M.; Holstein, J.; Robers, M.B.; Corona, C.R.; Gehringer, M.; Pfaffenrot, E.; Ghoreschi, K.; Knapp, S.; Laufer, S.A. Sselective Jak3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chem. Biol., 2016, 23, 1335-1340.
[131]
Hurley, C.A.; Blair, W.S.; Bull, R.J.; Chang, C.; Crackett, P.H.; Deshmukh, G.; Dyke, H.J.; Fong, R.; Ghilardi, N.; Gibbons, P.; Hewitt, P.R.; Johnson, A.; Johnson, T.; Kenny, J.R.; Kohli, P.B.; Kulagowski, J.J.; Liimatta, M.; Lupardus, P.J.; Maxey, R.J.; Mendonca, R.; Narukulla, R.; Pulk, R.; Ubhayakar, S.; van Abbema, A.; Ward, S.I.; Waszkowycz, B.; Zak, M. Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1. Bioorg. Med. Chem. Lett., 2013, 23, 3592-3598.
[133]
F. Hoffmann-La Roche AG. Tricyclic heterocyclic compounds,
compositions and methods of use thereof as Jak inhibitors.
WO 2013007768, 2013.
[134]
Siu, T.; Kumarasinghe, S.E.; Altman, M.D.; Katcher, M.; Northrup, A.; White, C.; Rosenstein, C.; Mathur, A.; Xu, L.; Chan, G.; Bachman, E.; Bouthillette, M.; Dinsmore, C.J.; Marshall, C.G.; Young, J.R. The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimization. Bioorg. Med. Chem. Lett., 2014, 24, 1466-1471.
[135]
Zimmermann, K.; Sang, X.; Mastalerz, H.A.; Johnson, W.L.; Zhang, G.; Liu, Q.; Batt, D.; Lombardo, L.J.; Vyas, D.; Trainor, G.L.; Tokarski, J.S.; Lorenzi, M.V.; You, D.; Gottardis, M.M.; Lippy, J.; Khan, J.; Sack, J.S.; Purandare, A.V. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors. Bioorg. Med. Chem. Lett., 2015, 25, 2809-2812.
[136]
Bristol-Myers Squibb Co. Carbazole and carboline kinase
inhibitors. WO 2010080474, 2010.
[137]
Gigante, M.; Pontrelli, P.; Herr, W.; Gigante, M.; D’Avenia, M.; Zaza, G.; Cavalcanti, E.; Accetturo, M.; Lucarelli, G.; Carrieri, G.; Battaglia, M.; Storkus, W.J.; Gesualdo, L.; Ranieri, E. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. J. Transl. Med., 2016, 14, 84.